March 4, 2009 – A Canadian bio-technology company, Sanomune Inc., has licensed a new treatment method that helps drugs to reach the brain unlike any other treatment for neurological diseases. The treatment method, developed by HealthPartners Research Foundation, is a new therapeutic technology offering hope to the 5.2 million people in the United States living with Alzheimer’s disease and other neurological diseases.
The intranasal method was developed by William H. Frey II, Ph.D., senior director of HealthPartners Research Foundation’s Alzheimer’s Research Center, and his colleagues. It allows medication to bypass the protective blood-brain barrier and enter the brain directly. Dr. Frey developed a way to bypass the barrier for neurological conditions using intranasal delivery of Deferoximine or SAN-121. SAN-121 has previously been shown when given in twice daily injections to reduce cognitive decline in Alzheimer’s patients by 50 percent. However, systemic delivery has unwanted and negative side effects including a drop in blood pressure. With intranasal delivery, side effects can be significantly reduced... Sanomune's Press Release -
